E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Subjects with subjective cognitive decline. |
sujetos con deterioro cognitivo subjetivo. |
|
E.1.1.1 | Medical condition in easily understood language |
Subjects with subjective cognitive decline. |
sujetos con deterioro cognitivo subjetivo. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10032831 |
E.1.2 | Term | Other specified non-arthropod-borne viral diseases of central nervous system |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To assess safety of a single dose of FBB followed by PET scan in individuals with subjective cognitive decline (SCD). 2. To determine the number of SCD subjects with positive visual FBB-PET scan. |
1. Evaluar la seguridad de una dosis única de FBB tras la realización de un PET-scan en sujetos con deterioro cognitivo subjetivo (DCS). 2. Determinar el número de sujetos con DCS con FBB-PET scan positivo visualmente. |
|
E.2.2 | Secondary objectives of the trial |
1. To determine the number of SCD subjects with positive standardized uptake value ratios (SUVRs) of FBB-PET scan. 2. To explore the cortical pattern of amyloid deposition in SCD subjects. |
1. Determinar el número de sujetos con DCS con FBB-PET scan positivo según ratios de valor de captación estándar (SUVRs). 2. Explorar el patrón cortical de depósito de amiloide en sujetos con DCS. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. According to the principal investigator, participants must be committed to participate and complete all study procedures. 2. The patient must report a memory problem (in isolation or in combination with complaints in other domains) with concern. 3. Age >/= 60*. 4. MMSE cutoff for inclusion will be ≥ 26. 5. CDR<0.5. 6. Has signed the Informed Consent Form voluntarily to participate in the study.
* Women of childbearing potential must agree to sexual abstinence, barrier or hormonal contraceptive methods during the study. |
1. Según el investigador principal, los participantes deben comprometerse a participar y completar todos los procedimientos del estudio. 2. El paciente debe informar de un problema de memoria (de forma aislada o en combinación con las quejas de otras esferas) con preocupación. 3. Edad > / = 60*. 4. MMSE cuyo punto de corte para la inclusión será ≥ 26. 5. CDR<0.5. 6. Haya firmado el formulario de consentimiento informado para participar voluntariamente en el estudio.
* Las mujeres en edad fértil deben estar de acuerdo con la abstinencia sexual, barrera o métodos anticonceptivos hormonales durante el estudio. |
|
E.4 | Principal exclusion criteria |
1. Subjects those are not able to complete the study. 2. Any major disease or history of a major disease, especially hepatobilliar disease (AST /ALT ≥ 5 x ULN) or advanced renal insufficiency (creatinine ≥ 2 x ULN). 3. Current or previous history of alcohol abuse or epilepsy. 4. Allergic to Florbetaben or any of its constituents. 5. Multiple drug allergies and/or previous history of contrast allergy. 6. Any disease or history of disease which, in the opinion of the investigator, can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function). 7. Evidence for any other neurological or psychiatric disease, eg. parkinsonism, history of stroke or seizure. 8. Pregnancy or breast feeding or planned pregnancy during the study period. |
1. Los sujetos que no son capaces de completar el estudio. 2. Cualquier enfermedad importante o antecedentes de una enfermedad importante, especialmente enfermedad hepatobilliar (AST / ALT ≥ 5 x LSN) o insuficiencia renal avanzada (creatinina ≥ 2 x LSN). 3. Historia actual o anterior de abuso de alcohol o la epilepsia. 4. Alergia a Florbetaben o cualquiera de sus componentes. 5. Alergia a múltiples medicamentos y / o antecedentes de alergia al contraste. 6. Cualquier enfermedad o historia de enfermedad que, en opinión del investigador, puede causar trastornos de la función cerebral (por ejemplo, el déficit de vitamina B12 o ácido fólico, función tiroidea alterada). 7. Evidencia de cualquier otra enfermedad neurológica o psiquiátrica, por ejemplo: parkinsonismo, antecedentes de accidente cerebrovascular o convulsión. 8. Embarazo o lactancia o embarazo planificado durante el período de estudio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Incidence of Adverse events of a single dose of FBB followed by PET scan in individuals with SCD. 2. Proportion of SCD subjects that present positive uptake after FBB-PET through visual examination. |
1. Incidencia de eventos adversos tras una dosis única de FBB en la realización del PET scan en sujetos con deterioro cognitivo subjetivo (DCS). 2. Proporción de sujetos con DCS que presentan un FBB-PET positiva tras la valoración visual. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. SUSARs, SAEs, death. 2. Proportion of FBB-PET with positive result through visual examination. |
1. SUSARs, SAEs, muerte. 2. Porporción de FBB-PET con resultado positivo tras la valoración visual. |
|
E.5.2 | Secondary end point(s) |
1. Proportion of SCD subjects presenting standardized uptake value ratios (SUVRs) of FBB-PET higher than 1,4. 2. The cortical pattern of amyloid deposition in SCD subjects at visual and semi-quantitative examination. |
1. Porporción de sujetos con DCS que presentan un SUVRs en el FBB-PET superior a 1,4. 2. El patrón cortical de depósito de amiloide en sujetos con DCS en la valoración visual y semi-cuantitativa. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Proportion of SCD subjects presenting standardized uptake value ratios (SUVRs) of FBB-PET higher than 1,4. 2. The cortical pattern of amyloid deposition in SCD subjects at visual and semi-quantitative examination. |
1. Porporción de sujetos con DCS que presentan un SUVRs en el FBB-PET superior a 1,4. 2. El patrón cortical de depósito de amiloide en sujetos con DCS en la valoración visual y semi-cuantitativa. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
No comparador |
No comparator |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |